NR4A1 and breast carcinoma: More than 90% of cases are not metastatic at diagnosis and for stage I, the 5-year breast cancer-specific survival is about 99% for hormone receptor-positive breast cancer, ≥94% in HER2-positive disease, and ≥85% in triple-negative patients.